Shuttle Pharmaceuticals Holdings, Inc.

Develops drugs to enhance radiation therapy for cancer and offers predictive diagnostics.

SHPH | US

Overview

Corporate Details

ISIN(s):: US8256933024
LEI:
Country:: United States of America
Address:: 401 PROFESSIONAL DRIVE, 20879 GAITHERSBURG
Website:: https://shuttlepharma.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company dedicated to improving outcomes for cancer patients by enhancing the effectiveness of radiation therapy (RT). The company develops novel therapies designed to sensitize cancer cells to radiation while protecting healthy tissues. Its lead product candidate, Ropidoxuridine, is a Phase II clinical-stage oral radiation sensitizer. The development pipeline also includes a portfolio of pre-clinical selective histone deacetylase (HDAC) inhibitors. In addition to therapeutics, Shuttle Pharma is developing diagnostic technologies, such as predictive blood tests for prostate cancer patients, to inform therapeutic decision-making and patient management. The company utilizes a proprietary drug discovery platform and strategic collaborations to advance its mission of increasing cancer cure rates and improving patient quality of life.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Shuttle Pharmaceuticals Holdings, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Shuttle Pharmaceuticals Holdings, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Shuttle Pharmaceuticals Holdings, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Arcellx, Inc. Engineering controllable cell therapies for cancer and autoimmune diseases.	United States of America	ACLX
Arctic Bioscience Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.	Norway	ABS
ArcticZymes Technologies Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.	Norway	AZT
Arcturus Therapeutics Holdings Inc. Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.	United States of America	ARCT
Arcus Biosciences, Inc. A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.	United States of America	RCUS
Arcutis Biotherapeutics, Inc. Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.	United States of America	ARQT
ARDELYX, INC. Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.	United States of America	ARDX
ARECOR THERAPEUTICS PLC Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.	United Kingdom	AREC
argenx SE Develops first-in-class antibody therapies for severe autoimmune diseases.	Netherlands	1AE
ARGENX SE Develops antibody-based therapies for severe autoimmune diseases, including its lead drug VYVGART.	United States of America	ARGX